APO RESEARCH · REPORT
Viral Vector and Plasmid DNA
Viral vectors carry genetic material into cells by exploiting the molecular mechanisms by which viruses transmit their genomes to other cells for infection.It can occur in vivo or in vitro.Plasmid carriers are plasmids artificially constructed on the basis of natural plasmids to adapt to laboratory operations.In recent years, global viral vector and plasmid DNA manufacturing has developed rapidly, with a compound growth rate of about 28% during 2018-2018.In 2018, global sales of viral vector and plasmid DNA production reached $381 million.In 2018, China accounted for about 4% of global sales.In the next five years, the production of viral vectors and plasmid DNA products in China will continue to grow rapidly.Viral vector and plasmid DNA manufacturing are mainly divided into viral vector manufacturing and plasmid DNA manufacturing, among which viral vector manufacturing accounts for the largest proportion, accounting for nearly 38% of the total market in 2018.Viral vector and plasmid DNA manufacturing is mainly used for drug development and production of cancer, genetic diseases, viral infections and other diseases, among which cancer is the main application field, accounting for 35% in 2018.The market is highly competitive.Brammer Bio, Oxford BioMedica, Cobra Biologics, FinVector and Lonza are major suppliers.They have mastered key technologies and patents, and they have a fixed customer base. They have established a monopoly in the market.Gene therapy technology innovation and clinical trials have mushroomed in recent years, and a number of gene therapy projects have been approved for marketing in the United States, the European Union, China and other countries.The target of gene therapy has also been gradually expanded from single gene genetic diseases to malignant tumors, infectious diseases, cardiovascular diseases, autoimmune diseases, metabolic diseases and other major diseases.
Product & engineering
Understand the product.
Viral vectors carry genetic material into cells by exploiting the molecular mechanisms by which viruses transmit their genomes to other cells for infection.It can occur in vivo or in vitro.Plasmid carriers are plasmids artificially constructed on the basis of natural plasmids to adapt to laboratory operations.In recent years, global viral vector and plasmid DNA manufacturing has developed rapidly, with a compound growth rate of about 28% during 2018-2018.In 2018, global sales of viral vector and plasmid DNA production reached $381 million.In 2018, China accounted for about 4% of global sales.In the next five years, the production of viral vectors and plasmid DNA products in China will continue to grow rapidly.Viral vector and plasmid DNA manufacturing are mainly divided into viral vector manufacturing and plasmid DNA manufacturing, among which viral vector manufacturing accounts for the largest proportion, accounting for nearly 38% of the total market in 2018.Viral vector and plasmid DNA manufacturing is mainly used for drug development and production of cancer, genetic diseases, viral infections and other diseases, among which cancer is the main application field, accounting for 35% in 2018.The market is highly competitive.Brammer Bio, Oxford BioMedica, Cobra Biologics, FinVector and Lonza are major suppliers.They have mastered key technologies and patents, and they have a fixed customer base. They have established a monopoly in the market.Gene therapy technology innovation and clinical trials have mushroomed in recent years, and a number of gene therapy projects have been approved for marketing in the United States, the European Union, China and other countries.The target of gene therapy has also been gradually expanded from single gene genetic diseases to malignant tumors, infectious diseases, cardiovascular diseases, autoimmune diseases, metabolic diseases and other major diseases.
Selected research
Industry Research
Viral Vector and Plasmid DNA Industry Research Report 2026
Market perspective
Viral vectors carry genetic material into cells by exploiting the molecular mechanisms by which viruses transmit their genomes to other cells for infection.It can occur in vivo or in vitro.Plasmid carriers are plasmids artificially constructed on the basis of natural plasmids to adapt to laboratory operations.In recent years, global viral vector and plasmid DNA manufacturing has developed rapidly, with a compound growth rate of about 28% during 2018-2018.In 2018, global sales of viral vector and plasmid DNA production reached $381 million.In 2018, China accounted for about 4% of global sales.In the next five years, the production of viral vectors and plasmid DNA products in China will continue to grow rapidly.Viral vector and plasmid DNA manufacturing are mainly divided into viral vector manufacturing and plasmid DNA manufacturing, among which viral vector manufacturing accounts for the largest proportion, accounting for nearly 38% of the total market in 2018.Viral vector and plasmid DNA manufacturing is mainly used for drug development and production of cancer, genetic diseases, viral infections and other diseases, among which cancer is the main application field, accounting for 35% in 2018.The market is highly competitive.Brammer Bio, Oxford BioMedica, Cobra Biologics, FinVector and Lonza are major suppliers.They have mastered key technologies and patents, and they have a fixed customer base. They have established a monopoly in the market.Gene therapy technology innovation and clinical trials have mushroomed in recent years, and a number of gene therapy projects have been approved for marketing in the United States, the European Union, China and other countries.The target of gene therapy has also been gradually expanded from single gene genetic diseases to malignant tumors, infectious diseases, cardiovascular diseases, autoimmune diseases, metabolic diseases and other major diseases.
Global Viral Vector and Plasmid DNA key players include BioReliance, Oxford BioMedica, UniQure, Cobra Biologics, etc. Global top four manufacturers hold a share over 45%.
North America is the largest market, with a share about 50%, followed by Europe, and Asia-Pacific, both have a share over 40 percent.
Read the full market overview
In terms of product, Viral Vectors is the largest segment, with a share about 80%. And in terms of application, the largest application is Cancers, followed by Inherited Disorders, Viral Infections, etc.
Report Scope
This report quantifies the global Viral Vector and Plasmid DNA market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Viral Vector and Plasmid DNA.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Viral Vector and Plasmid DNA Market by Company
Brammer Bio
Oxford BioMedica
Cobra Biologics
FinVector
Lonza
BioReliance
MolMed
FUJIFILM Diosynth Biotechnologies
UniQure
Aldevron
Richter-Helm
Eurogentec
OBiO Technology
Yposkesi
Cell and Gene Therapy Catapult
MassBiologics
Biovian
VGXI
Gene Synthesis
PlasmidFactory
Jikai Gene
Viral Vector and Plasmid DNA Segment by Type
Plasmid DNA
Viral Vector
Viral Vector and Plasmid DNA Segment by Application
Cancer
Virus Infection
Hereditary Disease
Viral Vector and Plasmid DNA Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Viral Vector and Plasmid DNA market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Viral Vector and Plasmid DNA and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Viral Vector and Plasmid DNA.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Viral Vector and Plasmid DNA companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Plasmid DNA
- Viral Vector
Applications
- Cancer
- Virus Infection
- Hereditary Disease
Companies covered
- Brammer Bio
- Oxford BioMedica
- Cobra Biologics
- FinVector
- Lonza
- BioReliance
- MolMed
- FUJIFILM Diosynth Biotechnologies
- UniQure
- Aldevron
- Richter-Helm
- Eurogentec
- OBiO Technology
- Yposkesi
- Cell and Gene Therapy Catapult
- MassBiologics
- Biovian
- VGXI
- Gene Synthesis
- PlasmidFactory
- Jikai Gene
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Viral Vector and Plasmid DNA by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Plasmid DNA
- 2.2.3 Viral Vector
- 2.3 Viral Vector and Plasmid DNA by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Cancer
- 2.3.3 Virus Infection
- 2.3.4 Hereditary Disease
- 2.4 Assumptions and Limitations
3 Viral Vector and Plasmid DNA Breakdown Data by Type
- 3.1 Global Viral Vector and Plasmid DNA Historic Market Size by Type (2021-2026)
- 3.2 Global Viral Vector and Plasmid DNA Forecasted Market Size by Type (2027-2032)
4 Viral Vector and Plasmid DNA Breakdown Data by Application
- 4.1 Global Viral Vector and Plasmid DNA Historic Market Size by Application (2021-2026)
- 4.2 Global Viral Vector and Plasmid DNA Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Viral Vector and Plasmid DNA Market Perspective (2021-2032)
- 5.2 Global Viral Vector and Plasmid DNA Growth Trends by Region
- 5.2.1 Global Viral Vector and Plasmid DNA Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Viral Vector and Plasmid DNA Historic Market Size by Region (2021-2026)
- 5.2.3 Viral Vector and Plasmid DNA Forecasted Market Size by Region (2027-2032)
- 5.3 Viral Vector and Plasmid DNA Market Dynamics
- 5.3.1 Viral Vector and Plasmid DNA Industry Trends
- 5.3.2 Viral Vector and Plasmid DNA Market Drivers
- 5.3.3 Viral Vector and Plasmid DNA Market Challenges
- 5.3.4 Viral Vector and Plasmid DNA Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Viral Vector and Plasmid DNA Players by Revenue
- 6.1.1 Global Top Viral Vector and Plasmid DNA Players by Revenue (2021-2026)
- 6.1.2 Global Viral Vector and Plasmid DNA Revenue Market Share by Players (2021-2026)
- 6.2 Global Viral Vector and Plasmid DNA Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Viral Vector and Plasmid DNA Head Office and Area Served
- 6.4 Global Viral Vector and Plasmid DNA Players, Product Type & Application
- 6.5 Global Viral Vector and Plasmid DNA Manufacturers Established Date
- 6.6 Global Viral Vector and Plasmid DNA Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Viral Vector and Plasmid DNA Market Size (2021-2032)
- 7.2 North America Viral Vector and Plasmid DNA Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Viral Vector and Plasmid DNA Market Size by Country (2021-2026)
- 7.4 North America Viral Vector and Plasmid DNA Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Viral Vector and Plasmid DNA Market Size (2021-2032)
- 8.2 Europe Viral Vector and Plasmid DNA Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Viral Vector and Plasmid DNA Market Size by Country (2021-2026)
- 8.4 Europe Viral Vector and Plasmid DNA Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Viral Vector and Plasmid DNA Market Size (2021-2032)
- 9.2 Asia-Pacific Viral Vector and Plasmid DNA Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Viral Vector and Plasmid DNA Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Viral Vector and Plasmid DNA Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Viral Vector and Plasmid DNA Market Size (2021-2032)
- 10.2 South America Viral Vector and Plasmid DNA Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Viral Vector and Plasmid DNA Market Size by Country (2021-2026)
- 10.4 South America Viral Vector and Plasmid DNA Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Viral Vector and Plasmid DNA Market Size (2021-2032)
- 11.2 Middle East & Africa Viral Vector and Plasmid DNA Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Viral Vector and Plasmid DNA Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Viral Vector and Plasmid DNA Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Brammer Bio
- 12.1.1 Brammer Bio Company Information
- 12.1.2 Brammer Bio Business Overview
- 12.1.3 Brammer Bio Revenue in Viral Vector and Plasmid DNA Business (2021-2026)
- 12.1.4 Brammer Bio Viral Vector and Plasmid DNA Product Portfolio
- 12.1.5 Brammer Bio Recent Developments
- 12.2 Oxford BioMedica
- 12.2.1 Oxford BioMedica Company Information
- 12.2.2 Oxford BioMedica Business Overview
- 12.2.3 Oxford BioMedica Revenue in Viral Vector and Plasmid DNA Business (2021-2026)
- 12.2.4 Oxford BioMedica Viral Vector and Plasmid DNA Product Portfolio
- 12.2.5 Oxford BioMedica Recent Developments
- 12.3 Cobra Biologics
- 12.3.1 Cobra Biologics Company Information
- 12.3.2 Cobra Biologics Business Overview
- 12.3.3 Cobra Biologics Revenue in Viral Vector and Plasmid DNA Business (2021-2026)
- 12.3.4 Cobra Biologics Viral Vector and Plasmid DNA Product Portfolio
- 12.3.5 Cobra Biologics Recent Developments
- 12.4 FinVector
- 12.4.1 FinVector Company Information
- 12.4.2 FinVector Business Overview
- 12.4.3 FinVector Revenue in Viral Vector and Plasmid DNA Business (2021-2026)
- 12.4.4 FinVector Viral Vector and Plasmid DNA Product Portfolio
- 12.4.5 FinVector Recent Developments
- 12.5 Lonza
- 12.5.1 Lonza Company Information
- 12.5.2 Lonza Business Overview
- 12.5.3 Lonza Revenue in Viral Vector and Plasmid DNA Business (2021-2026)
- 12.5.4 Lonza Viral Vector and Plasmid DNA Product Portfolio
- 12.5.5 Lonza Recent Developments
- 12.6 BioReliance
- 12.6.1 BioReliance Company Information
- 12.6.2 BioReliance Business Overview
- 12.6.3 BioReliance Revenue in Viral Vector and Plasmid DNA Business (2021-2026)
- 12.6.4 BioReliance Viral Vector and Plasmid DNA Product Portfolio
- 12.6.5 BioReliance Recent Developments
- 12.7 MolMed
- 12.7.1 MolMed Company Information
- 12.7.2 MolMed Business Overview
- 12.7.3 MolMed Revenue in Viral Vector and Plasmid DNA Business (2021-2026)
- 12.7.4 MolMed Viral Vector and Plasmid DNA Product Portfolio
- 12.7.5 MolMed Recent Developments
- 12.8 FUJIFILM Diosynth Biotechnologies
- 12.8.1 FUJIFILM Diosynth Biotechnologies Company Information
- 12.8.2 FUJIFILM Diosynth Biotechnologies Business Overview
- 12.8.3 FUJIFILM Diosynth Biotechnologies Revenue in Viral Vector and Plasmid DNA Business (2021-2026)
- 12.8.4 FUJIFILM Diosynth Biotechnologies Viral Vector and Plasmid DNA Product Portfolio
- 12.8.5 FUJIFILM Diosynth Biotechnologies Recent Developments
- 12.9 UniQure
- 12.9.1 UniQure Company Information
- 12.9.2 UniQure Business Overview
- 12.9.3 UniQure Revenue in Viral Vector and Plasmid DNA Business (2021-2026)
- 12.9.4 UniQure Viral Vector and Plasmid DNA Product Portfolio
- 12.9.5 UniQure Recent Developments
- 12.10 Aldevron
- 12.10.1 Aldevron Company Information
- 12.10.2 Aldevron Business Overview
- 12.10.3 Aldevron Revenue in Viral Vector and Plasmid DNA Business (2021-2026)
- 12.10.4 Aldevron Viral Vector and Plasmid DNA Product Portfolio
- 12.10.5 Aldevron Recent Developments
- 12.11 Richter-Helm
- 12.11.1 Richter-Helm Company Information
- 12.11.2 Richter-Helm Business Overview
- 12.11.3 Richter-Helm Revenue in Viral Vector and Plasmid DNA Business (2021-2026)
- 12.11.4 Richter-Helm Viral Vector and Plasmid DNA Product Portfolio
- 12.11.5 Richter-Helm Recent Developments
- 12.12 Eurogentec
- 12.12.1 Eurogentec Company Information
- 12.12.2 Eurogentec Business Overview
- 12.12.3 Eurogentec Revenue in Viral Vector and Plasmid DNA Business (2021-2026)
- 12.12.4 Eurogentec Viral Vector and Plasmid DNA Product Portfolio
- 12.12.5 Eurogentec Recent Developments
- 12.13 OBiO Technology
- 12.13.1 OBiO Technology Company Information
- 12.13.2 OBiO Technology Business Overview
- 12.13.3 OBiO Technology Revenue in Viral Vector and Plasmid DNA Business (2021-2026)
- 12.13.4 OBiO Technology Viral Vector and Plasmid DNA Product Portfolio
- 12.13.5 OBiO Technology Recent Developments
- 12.14 Yposkesi
- 12.14.1 Yposkesi Company Information
- 12.14.2 Yposkesi Business Overview
- 12.14.3 Yposkesi Revenue in Viral Vector and Plasmid DNA Business (2021-2026)
- 12.14.4 Yposkesi Viral Vector and Plasmid DNA Product Portfolio
- 12.14.5 Yposkesi Recent Developments
- 12.15 Cell and Gene Therapy Catapult
- 12.15.1 Cell and Gene Therapy Catapult Company Information
- 12.15.2 Cell and Gene Therapy Catapult Business Overview
- 12.15.3 Cell and Gene Therapy Catapult Revenue in Viral Vector and Plasmid DNA Business (2021-2026)
- 12.15.4 Cell and Gene Therapy Catapult Viral Vector and Plasmid DNA Product Portfolio
- 12.15.5 Cell and Gene Therapy Catapult Recent Developments
- 12.16 MassBiologics
- 12.16.1 MassBiologics Company Information
- 12.16.2 MassBiologics Business Overview
- 12.16.3 MassBiologics Revenue in Viral Vector and Plasmid DNA Business (2021-2026)
- 12.16.4 MassBiologics Viral Vector and Plasmid DNA Product Portfolio
- 12.16.5 MassBiologics Recent Developments
- 12.17 Biovian
- 12.17.1 Biovian Company Information
- 12.17.2 Biovian Business Overview
- 12.17.3 Biovian Revenue in Viral Vector and Plasmid DNA Business (2021-2026)
- 12.17.4 Biovian Viral Vector and Plasmid DNA Product Portfolio
- 12.17.5 Biovian Recent Developments
- 12.18 VGXI
- 12.18.1 VGXI Company Information
- 12.18.2 VGXI Business Overview
- 12.18.3 VGXI Revenue in Viral Vector and Plasmid DNA Business (2021-2026)
- 12.18.4 VGXI Viral Vector and Plasmid DNA Product Portfolio
- 12.18.5 VGXI Recent Developments
- 12.19 Gene Synthesis
- 12.19.1 Gene Synthesis Company Information
- 12.19.2 Gene Synthesis Business Overview
- 12.19.3 Gene Synthesis Revenue in Viral Vector and Plasmid DNA Business (2021-2026)
- 12.19.4 Gene Synthesis Viral Vector and Plasmid DNA Product Portfolio
- 12.19.5 Gene Synthesis Recent Developments
- 12.20 PlasmidFactory
- 12.20.1 PlasmidFactory Company Information
- 12.20.2 PlasmidFactory Business Overview
- 12.20.3 PlasmidFactory Revenue in Viral Vector and Plasmid DNA Business (2021-2026)
- 12.20.4 PlasmidFactory Viral Vector and Plasmid DNA Product Portfolio
- 12.20.5 PlasmidFactory Recent Developments
- 12.21 Jikai Gene
- 12.21.1 Jikai Gene Company Information
- 12.21.2 Jikai Gene Business Overview
- 12.21.3 Jikai Gene Revenue in Viral Vector and Plasmid DNA Business (2021-2026)
- 12.21.4 Jikai Gene Viral Vector and Plasmid DNA Product Portfolio
- 12.21.5 Jikai Gene Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst